ResMed’s strong demand for AirSense 11 boosts its earnings outlook. Learn why RMD stock is undervalued with growth ...

In the wake of the U.S. Food and Drug Administration’s approval of Zepbound to treat moderate to severe obstructive sleep ...

ResMed’s competitive edge is strong, but its current valuation seems inflated. Read why RMD stock might be ripe for ...

The quarter saw ResMed continue its strategic expansion with significant investments in innovation, including the launch of new products like the AirTouch N30i mask, designed to enhance patient ...

(RTTNews) - Resmed Inc (RMD) revealed a profit for its second quarter that increased from last year and beat the Street estimates. The company's earnings totaled $344.6 million, or $2.34 per share.

ResMed stock tumbled Friday after organic sales growth slowed somewhat in the second fiscal quarter. But one analyst was upbeat.

Q2 2025 Management View CEO Michael Farrell reported 10% global revenue growth, driven by demand across the sleep health, breathing health, and residential care software portfolios. Device sales, ...

What is the current share price of ResMed Inc. (RMD)? ResMed Inc.'s (RMD) current share price is $37.69. This constitutes a price movement of 6.20% when compared to the share price 7 days ago and is ...

CSL Ltd (ASX: CSL) and ResMed Inc (ASX: RMD ... particularly in OSA masks and (3) Operating margin expansion driven by product mix and solid cost management. Goldman also points out that it ...

Led by growth in the U.S., ResMed’s first half achieved 12 per cent revenue growth over the same period last year, with devices and masks both growing by 11 per cent in constant currency terms during ...